Stock ANL ADLAI NORTYE LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Adlai Nortye Ltd.

Equities

ANL

US00704R1095

Market Closed - Nasdaq
Other stock markets
 15:58:52 2024-05-30 EDT 		5-day change 1st Jan Change
7.6 USD -7.99% Intraday chart for Adlai Nortye Ltd. -36.82% -15.46%
05-24 Adlai Nortye Ltd. Announces to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy At ASCO 2024 CI
05-22 Adlai Nortye Announces First Patient Dosed in Randomized Phase Ii Clinical Trial of Palupiprant for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy CI

Evolution of the average Target Price on Adlai Nortye Ltd.

Price target over the last 5 years

History of analyst recommendation changes

804c5640a67973d6eb89.cwkPXqsiWpbRwauhiK8qGdRFJjN5klUjHMwPt2ZxWHY.EWZmB9NmMcmi89L-2e5eba0VZF9L_T5XUIJt0w8oOSZLb2QJ8WM2_OepxA~49b0535a52c9f9b85b0b73c2fb6f31be

Analyst Recommendations on Adlai Nortye Ltd.

Cantor Fitzgerald Starts Adlai Nortye at Overweight With $30 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
7.7
Average target price
-

Consensus detail

Consensus revision (last 18 months)

Analysts covering Adlai Nortye Ltd.

Cantor Fitzgerald

Quarterly revenue - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ANL Stock
  4. Consensus Adlai Nortye Ltd.